DVT Risk in a 23-Year-Old Female on Progestin-Only Contraception
A healthy 23-year-old woman using progestin-only contraception has essentially no increased risk of deep vein thrombosis (DVT) compared to non-users of hormonal contraception, with the important exception of depot medroxyprogesterone acetate (DMPA/Depo-Provera) injections, which may double or triple the risk.
Risk Stratification by Progestin-Only Method Type
The 2024 CDC guidelines classify progestin-only contraceptives as Category 1 (no restriction) for women with DVT risk factors, in stark contrast to combined hormonal contraceptives 1. However, this broad classification masks important differences between delivery methods:
Low-to-No Risk Methods:
- Progestin-only pills (POPs): No increased DVT risk (relative risk 0.90,95% CI 0.57-1.45) 2
- Levonorgestrel IUD: No increased risk and possibly protective (relative risk 0.61,95% CI 0.24-1.53; odds ratio 0.3,95% CI 0.1-1.1) 2, 3
- Etonogestrel implant: No demonstrated increased risk 2, 4
Moderate Risk Method:
- DMPA (Depo-Provera) injections: 2.7-3.6 fold increased risk compared to non-users (95% CI 1.29-5.53 and 1.8-7.1, respectively) 2, 3
Clinical Context for Your 23-Year-Old Patient
At age 23 without additional risk factors, this woman's baseline absolute DVT risk is extremely low (approximately 0.01-0.02% per year). Even if she were using DMPA injections—the highest-risk progestin-only method—her absolute risk would remain under 0.1% per year, which is still substantially lower than the 0.05-0.1% annual risk associated with combined oral contraceptives 5.
For progestin-only pills or implants, her DVT risk remains essentially at baseline population levels.
Important Caveats and Risk Modifiers
The 2010 CDC Medical Eligibility Criteria assigns Category 2 (benefits generally outweigh risks) to progestin-only methods in women with 6:
- History of DVT/PE (regardless of recurrence risk)
- Known thrombophilia
- Major surgery with prolonged immobilization
- Multiple cardiovascular risk factors
This conservative classification reflects theoretical concerns rather than demonstrated harm, as the evidence shows no meaningful increased risk for non-injectable progestin methods even in these populations 2, 4.
Comparison to Combined Hormonal Contraceptives
Combined hormonal contraceptives (pills, patches, rings) carry a 3-6 fold increased DVT risk depending on the progestin type, with absolute risks of 0.05-0.15% per year in young healthy women 4, 5, 7. Progestin-only pills and implants do not share this risk profile, making them the preferred option when thrombotic risk is a concern 4.
Practical Recommendation
For your 23-year-old patient on progestin-only contraception (assuming pills, implant, or LNG-IUD), provide reassurance that her DVT risk is not meaningfully elevated above baseline. No additional screening, monitoring, or precautions are warranted beyond standard care. If she is using DMPA injections, acknowledge a small increased risk but emphasize that her absolute risk remains very low given her age and (presumed) absence of other risk factors.
The only scenario requiring method reconsideration would be if she develops additional major risk factors (active cancer, prolonged immobilization, confirmed thrombophilia) or experiences an actual thrombotic event—at which point DMPA should be discontinued but other progestin-only methods could still be considered 6.